Recursion Pharmaceuticals
clinical patient population large and diagnosable rare autosomal dominant tumor syndrome resulting from inactivation of the gene which leads to deficiencies in the tumor suppressor protein merlin can be inherited or spontaneous of patients represent new mutations up to are mosaic manifestations and vestibular mean age at presentation years no approved medical therapy no approved drugs for surgery is standard of care when feasible location may make complete resection untenable leading to hearing loss facial paralysis poor balance and visual difficulty disease overview neurofibromatosis type | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
97 of 143
Related slides by other companies
Mink Therapeutics
IPO
October 2021
phase clinical trial focused in solid tumors | Mink Therapeutics
Genprex
Investor Presentation
October 2022
tumor suppressor genes deleted during cancer development | Genprex
Kymera
IPO
August 2020
degrader clinical development plan in liquid and solid tumors | Kymera
RayzeBio
IPO
September 2023
lead clinical indication refractory tumors nets tumors of the tract net and pancreas net have limited als gses | RayzeBio
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io